Laddar...
Alzheimer's disease drug development and the problem of the blood-brain barrier
Alzheimer's disease (AD) drug development is limited by the presence of the blood-brain barrier (BBB). More than 98% of all small molecule drugs, and ∼100% of all large molecule drugs, do not cross the BBB. Despite the fact that the vast majority of AD drug candidates do not cross the BBB, the...
Sparad:
| Huvudupphovsman: | |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
2009
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2756824/ https://ncbi.nlm.nih.gov/pubmed/19751922 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jalz.2009.06.003 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|